Ankylosing%20spondylitis News

News

Original New Drug Application Approvals by US FDA (16-31 May 2023)

20230601065632

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1 - 15 December 2022)

20221219013320

New drug applications approved by US FDA as of 01 - 15 December 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Smoking, comorbidities, EAMs up death risk in hospitalized ankylosing spondylitis patients

20220720130000

Smoking, extra-articular manifestations (EAMs), and comorbidities are all associated with a higher risk of all-cause mortality in hospitalized patients with ankylosing spondylitis (AS) than those in the comparison cohort, reports a study.

Upadacitinib works in select ankylosing spondylitis patients

20220714080000

The Janus kinase inhibitor upadacitinib induces significantly higher response than placebo in ankylosing spondylitis patients with inadequate response to biological disease-modifying antirheumatic drugs, without introducing new safety signals, according to data from a phase III trial.

Women with rheumatic diseases face adverse pregnancy outcomes

Jairia Dela Cruz, 20220609140000

Pregnancies in women with rheumatic and systemic autoimmune diseases—including systemic lupus erythematosus, spondyloarthritis, and rheumatoid arthritis—pose significant health risks and are likely to lead to unfavourable outcomes, according to several studies presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.

TNFi halts radiographic sacroiliitis progression in axial spondyloarthritis

20220519060000

Treatment with tumour necrosis factor inhibitors (TNFis) in patients with early axial spondyloarthritis (axSpA) appears to put brakes on radiographic sacroiliitis progression, according to a study.

TNFi use does not induce hypertension in ankylosing spondylitis

20220325130000

Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.

First-line biologic therapy persists longer than later agents in ankylosing spondylitis

20220222130000

Biologic disease-modifying antirheumatic drug (bDMARD) therapy is effective in reducing ankylosing spondylitis (AS) disease activity, reports a study, noting how treatment has persisted for up to 8 years among patients remaining on their first bDMARD, which is longer than on subsequent agents.

Original New Drug Application Approvals by US FDA (16 - 31 December 2021)

20220106033253

New drug applications approved by US FDA as of 16-31 December 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Low pain tolerance predicts worse disease outcomes in axial spondyloarthritis

20211122110000

Chronic pain frequently occurs in patients with axial spondyloarthritis (axSpA), with no differences seen in any pain measures between those with ankylosing spondylitis (AS) and nonradiographic axSpA, a recent study has shown. In addition, higher pain sensitivity is predictive of having worse disease and health outcomes.

Product Highlight - Evenity

01 Dec 2021

Romosozumab 105 mg/1.17 mL soln for inj

Product Highlight - Idacio

13 Sep 2022

Adalimumab soln for inj 40 mg/0.8 mL

Product Highlight - Locoa

01 Dec 2021

Esflurbiprofen 40 mg transdermal patch